These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 9721789)
61. Detection of factor V Leiden in Thai patients with venous thrombosis. Prayoonwiwat W; Arnutti P; Hiyoshi M; Nathalang O; Suwanasophon C; Kokaseam R; Krutvecho T; Tatsumi N Asian Pac J Allergy Immunol; 2000 Jun; 18(2):105-8. PubMed ID: 10928623 [TBL] [Abstract][Full Text] [Related]
62. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Bloemenkamp KW; Rosendaal FR; Helmerhorst FM; Büller HR; Vandenbroucke JP Lancet; 1995 Dec; 346(8990):1593-6. PubMed ID: 7500751 [TBL] [Abstract][Full Text] [Related]
63. Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism--pooled analysis of 8 case-control studies including 2310 cases and 3204 controls. Study Group for Pooled-Analysis in Venous Thromboembolism. Emmerich J; Rosendaal FR; Cattaneo M; Margaglione M; De Stefano V; Cumming T; Arruda V; Hillarp A; Reny JL Thromb Haemost; 2001 Sep; 86(3):809-16. PubMed ID: 11583312 [TBL] [Abstract][Full Text] [Related]
64. A possible role for activated protein C resistance in patients with first and second trimester pregnancy failure. Tal J; Schliamser LM; Leibovitz Z; Ohel G; Attias D Hum Reprod; 1999 Jun; 14(6):1624-7. PubMed ID: 10357988 [TBL] [Abstract][Full Text] [Related]
65. A comparison between two activated protein C resistance methods as routine diagnostic tests for factor V Leiden mutation. Aboud MR; Ma DD Br J Haematol; 1997 Jun; 97(4):798-803. PubMed ID: 9217178 [TBL] [Abstract][Full Text] [Related]
66. Laboratory assessment of Activated Protein C Resistance/Factor V-Leiden and performance characteristics of a new quantitative assay. Amiral J; Vissac AM; Seghatchian J Transfus Apher Sci; 2017 Dec; 56(6):906-913. PubMed ID: 29162399 [TBL] [Abstract][Full Text] [Related]
67. Venous thromboembolism in carriers of the Factor V Leiden mutation and in patients without known thrombophilic risk factor; prediction of recurrence and APC-PCI complex concentration and/or soluble thrombomodulin antigen and activity. Strandberg K; Svensson PJ; Ohlin AK Thromb Res; 2007; 121(2):145-51. PubMed ID: 17499343 [TBL] [Abstract][Full Text] [Related]
68. Molecular characterization of a type I quantitative factor V deficiency in a thrombosis patient that is "pseudo homozygous" for activated protein C resistance. Guasch JF; Lensen RP; Bertina RM Thromb Haemost; 1997 Feb; 77(2):252-7. PubMed ID: 9157576 [TBL] [Abstract][Full Text] [Related]
69. Pulmonary embolism and deep venous thrombosis during pregnancy or oral contraceptive use: prevalence of factor V Leiden. Hirsch DR; Mikkola KM; Marks PW; Fox EA; Dorfman DM; Ewenstein BM; Goldhaber SZ Am Heart J; 1996 Jun; 131(6):1145-8. PubMed ID: 8644593 [TBL] [Abstract][Full Text] [Related]
70. Factor V Leiden mutation and type 1 diabetes mellitus. Demirer AN; Alikasifoglu M; Tuncbilek E; Karakus S; Erbas T Blood Coagul Fibrinolysis; 2008 Jan; 19(1):70-4. PubMed ID: 18180619 [TBL] [Abstract][Full Text] [Related]
71. Factor V Leiden and other coagulation factor mutations affecting thrombotic risk. Bertina RM Clin Chem; 1997 Sep; 43(9):1678-83. PubMed ID: 9299960 [TBL] [Abstract][Full Text] [Related]
72. Oral contraceptives enhance the risk of clinical manifestation of venous thrombosis at a young age in females homozygous for factor V Leiden. Rintelen C; Mannhalter C; Ireland H; Lane DA; Knöbl P; Lechner K; Pabinger I Br J Haematol; 1996 May; 93(2):487-90. PubMed ID: 8639453 [TBL] [Abstract][Full Text] [Related]
73. Endogenous thrombin potential for predicting risk of venous thromboembolism in carriers of factor V Leiden. Lincz LF; Lonergan A; Scorgie FE; Rowlings P; Gibson R; Lawrie A; Seldon M Pathophysiol Haemost Thromb; 2006; 35(6):435-9. PubMed ID: 17565236 [TBL] [Abstract][Full Text] [Related]
74. Increased resistance to activated protein C and factor V Leiden in recurrent abortions. Review of other hypercoagulability factors. Hatzis T; Cardamakis E; Drivalas E; Makatsoris K; Bevan D; Pantos C; Malliopoulou V; Tsagaris N; Kreatsa O; Antoniadi T; Petersen MB; Karageorgiou H; Mantouvalos H Eur J Contracept Reprod Health Care; 1999 Sep; 4(3):135-44. PubMed ID: 10574639 [TBL] [Abstract][Full Text] [Related]
75. Prevalence of resistance against activated protein C resulting from factor V Leiden is significantly increased in myocardial infarction: investigation of 507 patients with myocardial infarction. Middendorf K; Göhring P; Huehns TY; Seidel D; Steinbeck G; Nikol S Am Heart J; 2004 May; 147(5):897-904. PubMed ID: 15131548 [TBL] [Abstract][Full Text] [Related]
76. Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women. Rosendaal FR; Siscovick DS; Schwartz SM; Beverly RK; Psaty BM; Longstreth WT; Raghunathan TE; Koepsell TD; Reitsma PH Blood; 1997 Apr; 89(8):2817-21. PubMed ID: 9108400 [TBL] [Abstract][Full Text] [Related]
77. Use of selective factor V Leiden screening in pregnancy to identify candidates for anticoagulants. Lindqvist PG; Olofsson P; Dahlbäck B Obstet Gynecol; 2002 Aug; 100(2):332-6. PubMed ID: 12151159 [TBL] [Abstract][Full Text] [Related]
78. False findings of low protein C activity in two children with Budd-Chiari syndrome and factor V Leiden mutation. Ozçay F; Ozbek N Haematologia (Budap); 2002; 32(1):11-5. PubMed ID: 12243550 [TBL] [Abstract][Full Text] [Related]
79. Factor V Leiden-like behaviour of animal plasma and its use for calibration of activated protein C-dependent assays. Kraus M; Römisch J Blood Coagul Fibrinolysis; 1996 Apr; 7(3):295-302. PubMed ID: 8735136 [TBL] [Abstract][Full Text] [Related]
80. Stroke in a neonate heterozygous for factor V Leiden. Varelas PN; Sleight BJ; Rinder HM; Sze G; Ment LR Pediatr Neurol; 1998 Mar; 18(3):262-4. PubMed ID: 9568926 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]